NCT01681433 - OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 21, 2017

Study Completion Date

June 21, 2017

Conditions

Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA

Interventions

DRUG

OGX-427

OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV

DRUG

Abiraterone Acetate

Standard therapy: Abiraterone Acetate 1000 mg PO daily

DRUG

Prednisone

Standard therapy: Prednisone 10-20 mg PO daily

Trial Locations (16)

23502

Virginia Oncology Associates, Norfolk

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

46219

IU Health Central Indiana Cancer Centers, Indianapolis

46527

IU Health Goshen Hospital, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

47403

IU Health Bloomington Hospital, Bloomington

55905

Mayo Clinic, Rochester

87131

University of New Mexico Cancer Center: Albuquerque, Albuquerque

90292

Prostate Oncology Specialists, Inc., Marina del Rey

02115

Dana Farber Cancer Institute, Boston

T2N 4N2

Alberta Health Services: Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency, Vancouver

R3E 0V9

Cancer Care Manitoba, Winnipeg

L8V 5C2

Juravinski Cancer Centre, Hamilton

H2L 4M1

Centre Hospitalier de l'Université de Montréal, Montreal